• About Us
  • About PhAMA
  • Industry Overview
  • FAQ
  • Contact Us
• Our People
  • Board of Directors
  • Past Leaders
  • Secretariat
  • Members
  • Join PhAMA
• Our Work
  • Industry Support
  • Strategic Partnerships
  • Advocacy
  • Committees
  • Capability Building
• Resources
  • International Networks
  • National Networks
• Initiatives
  • Malaysia Cancer Care Coalition (M3C)
  • PhAMA Self Care White Paper
• Publications
  • Guiding Principles
  • Fact Book
  • Archives
• Events

Announcements

Quick Search Article:

Category:

All DCA letters General News MAB Letter NPCB

Search

There are 26 records that matched your search criteria

Date	Title	Category
14-Sep-2009	Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009	DCA letters
14-Sep-2009	Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009	DCA letters
14-Sep-2009	Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009	DCA letters
14-Jun-2011	Joint MyIPO-PhAMA Seminar on '1 Malaysia Medicines: The Way Forward in Intellectual Property' MyIPO Office, Level 12A, Menara UOA, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur
14-Jun-2011	MyIPO-PhAMA IP Seminar on Intellectual Property: 'The Way Forward' - Post event Videos and Photos The MyIPO-PhAMA IP Seminar on Intellectual Property: "The Way Forward", was held on Tuesday 14 June 2011 at the...
24-Mar-2016	44th PhAMA Annual General Meeting 2016